Back to Search
Start Over
Ongoing Response in a Multiply Relapsed Metastatic Posterior Fossa Ependymoma A After Vorinostat and Concomitant Irradiation
- Source :
- Journal of Pediatric Hematology/Oncology. 44:e576-e579
- Publication Year :
- 2021
- Publisher :
- Ovid Technologies (Wolters Kluwer Health), 2021.
-
Abstract
- Posterior fossa ependymomas A confer the worst prognosis among all subtypes. They demonstrate distinct epigenetic changes, which can be targeted with epigenetic modifiers like histone deacetylase inhibitors (Vorinostat). We describe a 3-year-old male diagnosed with a posterior fossa ependymoma who had a number of recurrences requiring multimodal therapy. Molecular analysis demonstrated a BCL-6 corepressor mutation, and methylation profiling matched with posterior fossa ependymomas A. He received craniospinal irradiation and focal boost with Vorinostat. Serial imaging after irradiation revealed a progressively decreasing tumor burden with nearly complete resolution of disease at 15 months. Histone deacetylase inhibitors demonstrate promise in treatment of carefully selected cases of ependymoma.
- Subjects :
- Male
Ependymoma
Vorinostat
business.industry
Multimodal therapy
Hematology
medicine.disease
Combined Modality Therapy
Craniospinal Irradiation
Histone Deacetylase Inhibitors
Text mining
Oncology
Child, Preschool
Concomitant
Pediatrics, Perinatology and Child Health
Cancer research
Humans
Medicine
Epigenetics
Histone deacetylase
business
medicine.drug
Subjects
Details
- ISSN :
- 10774114
- Volume :
- 44
- Database :
- OpenAIRE
- Journal :
- Journal of Pediatric Hematology/Oncology
- Accession number :
- edsair.doi.dedup.....86f1ba16b8f5883eced9a3f9f1690bfc